If Your Evidence Lands as Noise, It Isn’t Evidence Yet.
Stay Informed
Get insights delivered to your inbox
Subscribe to receive the latest research, perspectives, and strategic insights from Shapiro+Raj.
Key Takeaways
-
When strong clinical evidence lands as noise in the market, the instinct is to add more proof — another endpoint, another chart, a denser leave-behind. That's the wrong fix, because the problem was never insufficient evidence.
-
Complex value that hasn't been translated into a story the audience can hold, believe, and repeat isn't value. It's complexity — and complexity reads as noise.
-
More message testing doesn't solve this either. It scores the noise, telling you which version of the untranslated message tested least badly, not what would actually land.
-
Effective message testing has to distinguish what's clinically differentiating from what's genuinely motivating, determine what the audience needs to hear first, and check whether the story survives retelling in the real world.
-
The first version of a story the market hears is the one it keeps. Translating late means spending years correcting a first impression that could have been gotten right from the start.
In short: When strong evidence isn’t landing, the fix is translation, not more proof — understanding exactly what the audience needs to understand and believe before they’ll move, and building the story around that, not around what’s merely correct.
When I came to this country as a young man, I arrived with a full vocabulary and no ability to be understood.
I don’t mean the language — I spoke English. I mean I would say something true, something I was sure of, and watch it land in the room as noise. The content was right. The translation was missing. It took me years to learn that being understood is not the same as being correct, and that the gap between them is where you either connect or disappear.
I’ve watched a lot of brands live in that gap ever since.
Why Does Strong Clinical Evidence Sometimes Land as Noise in the Market?
The evidence is genuinely strong. The clinical story holds, the differentiation is real, the value is there for anyone who reads the full data set. And in the market, it lands as noise. The message testing comes back muddy. The campaign underperforms. The field says customers “aren’t getting it.” And the instinct — always — is to add more proof. Another endpoint. Another chart. A denser leave-behind.
More proof is exactly the wrong medicine. The problem was never insufficient evidence. The problem is that complex value which hasn’t been translated is not value. It’s complexity. And complexity is noise.
That pattern shows up in how HCPs actually process pharma messaging in practice. Industry analysis of message-recall data across hundreds of pharma brands found that when HCPs recalled more than five brand messages, their likelihood of prescribing dropped sharply — the sweet spot sat closer to three or four clearly retained messages, not a denser stack of claims.¹ Adding more doesn’t add understanding. Past a point, it actively works against it.
Why Doesn’t More Message Testing Fix an Untranslated Story?
This is the cleanest illustration of a factor going to zero. You can have the best data in the category — the Better Data factor maxed out — and if the Deeper Insight that turns it into a story the human brain can hold, believe, and repeat is missing, the whole thing multiplies to nothing.
Inert. A room full of correct information no one can act on. And more message testing doesn’t fix it — it scores the noise. It tells you which version of the untranslated thing tested least badly.
What Should Effective Message Testing Actually Determine?
Effective message testing has to go further. It must distinguish what is clinically differentiating from what is genuinely motivating, determine what the audience needs to hear first, and reveal whether the proposed story can survive retelling in the real world.
That matters because the brand team’s preferred narrative order is not always the order customers can most readily understand, believe, and act on. The goal is not simply to select winning claims; it is to build the sequence that turns those claims into a coherent, repeatable story.
This is also why a strong differentiator can still fail to stick with HCPs — not because it’s wrong, but because it’s too complex to recall, poorly sequenced, or genuinely not what that specific audience is listening for at that moment.² Correct and understood are not the same test, and message testing that only checks for correctness will miss it every time.
Why Does Timing Matter for How a Story Gets Told?
What you actually need is the insight into what your customer must understand and believe before they’ll move, and then the translation of your evidence into exactly that. Not louder. Not denser. Clearer, in the specific way this specific audience receives meaning.
The window matters, too, because the first version of your story the market hears is the one it keeps. Translate late, and you spend years correcting a first impression you could have gotten right the first time.
What Should Brand and Medical Teams Reach For Instead of More Evidence?
So don’t reach for more evidence.
When your value lands as noise, reach for the translation. Ask what your customer has to understand and believe — and whether your story is built to deliver exactly that, or merely to be correct.
That’s the work my team at Shapiro+Raj does as a life sciences insights consultancy. We don’t help you say more. We help you be understood — which, I promise you from personal experience, is the harder and more valuable thing.
Correct was never the goal. Understood is. I learned that the slow way. Your brand doesn’t have to.
See how Shapiro+Raj transformed a rich, complex clinical data package into one differentiated global narrative—testing both what messages mattered and how the story needed to unfold
¹ ZoomRx data reported in “Pharma Marketers: Keep Oncology HCP Messaging Short with a Compelling Brand Story,” Fierce Pharma.
² MMIT, “Measuring Message Efficacy: How to Change HCP Brand Perceptions.”
Frequently asked questions
Why does strong clinical evidence sometimes fail to resonate with HCPs or patients?
Strong evidence can still land as noise when it hasn’t been translated into a story the audience can hold, believe, and repeat. The underlying data being correct doesn’t guarantee it’s been communicated in a way the specific audience actually processes and retains.
Why doesn't adding more clinical data points fix a message that isn't landing?
More proof adds complexity, not clarity. Once a message becomes too dense to recall clearly, comprehension and impact tend to decline — industry message-recall research shows HCPs who retain more than roughly five brand messages become measurably less likely to act on them.¹
What's the difference between message testing for correctness and message testing for comprehension?
Testing for correctness checks whether claims are accurate and well-supported. Testing for comprehension and translation goes further — it identifies what’s genuinely motivating versus merely differentiating, determines what the audience needs to hear first, and checks whether the story holds up when retold, not just when read.
Why does the order in which claims are presented matter in pharma messaging?
The sequence in which an audience receives information affects whether they can understand, believe, and act on it — and that sequence isn’t always the order a brand team would naturally lead with internally. Building the right sequence is part of translation, not an afterthought to it.
Why is it important to get pharma messaging right the first time rather than refining it later?
The first version of a story a market hears tends to be the one it keeps. Correcting an early impression after it has settled in generally takes far longer than getting the translation right at launch.
How does Shapiro+Raj's approach to message testing differ from standard pharma market research?
As a life sciences insights consultancy, Shapiro+Raj focuses on translation — identifying exactly what an audience needs to understand and believe before they’ll act — rather than simply testing which version of a claim set scores best on recall or preference.